RxDoctor Payments Data

Harold Smith, PA

Physician Assistant · Concord, NCNPI 1174590590

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $20,350 of the $25,010 with a category attached, or 81.4%. AbbVie accounts for 93.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $23,298 and has fallen 99.4% since, to $134 in 2025. Among physician assistant clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,010in general payments, 2019–2025

Across 59 payments — averaging $423.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$23K
  • Bayer$1K
  • Averitas Pharma Inc.$156
  • Novo Nordisk$125
  • Neurocrine Biosciences, Inc.$122
  • Eisai Inc.$105
  • plus $34 from 2 others

What the payments were for

  • Consulting fees$1050%
  • Speaking & faculty fees$20,35081%
  • Travel & lodging$3,40214%
  • Food & beverage$1,1545%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,010 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$14,603
Medicare patients
69
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide48$62,826
EliquisApixaban37$53,449
Tresiba Flextouch U-200Insulin Degludec32$37,707
OzempicSemaglutide20$19,575
FarxigaDapagliflozin Propanediol13$17,808
JanuviaSitagliptin Phosphate16$14,934
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$12,905
LinzessLinaclotide14$11,688
SynthroidLevothyroxine Sodium20$1,959
Omeprazole107$1,422
Wixela InhubFluticasone Propion/Salmeterol11$1,353
Gabapentin63$1,199
Atorvastatin Calcium137$1,109
Duloxetine Hcl31$939
Fluticasone Propionate54$927

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$125$19,57520 claims
AstraZenecaFarxiga$14$17,80813 claims
AbbVieLinzess, Synthroid$23,406$13,64834 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Concord

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →